Extended Data Fig. 8: Fate mapping of Flt3Cretg/+ R26Tom/+ mice after Cyclophosphamide treatment.
a, Blood cell counts (mean ± s.e.m.) of 7–11 week old Flt3Cretg/+ R26Tom/+ mice before and after Cyclophosphamide (CP) treatment (day 0), relative to untreated baseline. Analysis on day -3 (baseline, n = 19), 4 (n = 13), 7 (n = 13), 18 (n = 10), and 45 (n = 7). All 19 mice with baseline measurement were bled on at least one additional time point; 7 of them were bled at all time points. Compared to baseline, *P = 2.27 × 10−2 for d4 in platelets; in erythrocytes ****P = 8.54 × 10−6 for d4, ****P = 4.81 × 10−8 for d7 and ***P = 1.88 × 10−3 for d18; in leukocytes ****P = 4.09 × 10−36 for d4, ****P = 2.56 × 10−7 for d18 and ***P = 1.72 × 10−3 for d45. Linear mixed-model two-sided analysis with P-value adjustment by Benjamini-Hochberg procedure. b, BM MkP and CFU-E progenitor cell counts (mean ± s.e.m.) in Flt3Cretg/+ R26Tom/+ mice on day 4 following CP treatment (n = 4), relative to untreated mice (n = 4). Both progenitor counts were significantly decreased (*P = 0.03); two-tailed Mann-Whitney test. c, Representative flow cytometry profiles (% of parent gates) of blood lineages of an 8 week old Flt3Cretg/+ R26Tom/+ mouse before and after CP treatment. d, Flt3Cre-tdTomato expression (mean ± s.e.m. % of parent gate) in BM LIN−cKIT+FLT3+ progenitor cells of Flt3Cretg/+ R26Tom/+ mice before and after CP treatment. Untreated (n = 4), and day 4 (n = 4), 7 (n = 4), 18 (n = 6), 45 (n = 7) after CP.
